Inhibition of cytochrome P450 enzymes by quinones and anthraquinones

Chemical Research in Toxicology

Volumn 25, Issue 2, 2012, Pages 357-365

  Sridhar, Jayalakshmi ^a   Liu, Jiawang ^a   Foroozesh, Maryam ^a   Stevens, Cheryl L Klein ^a  

^a XAVIER UNIVERSITY OF LOUISIANA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 AMINO 4 CHLORO 2 METHYLANTHRACENE 9,10 DIONE; 1 AMINO 4 HYDROXYANTHRACENE 9,10 DIONE; 2,6 DI TERT BUTYL 5 HYDROXYNAPHTHALENE 1,4 DIONE; CYTOCHROME P450; CYTOCHROME P450 1A1; CYTOCHROME P450 1A2; CYTOCHROME P450 2A6; CYTOCHROME P450 2B1; CYTOCHROME P450 INHIBITOR; EMODIN; METHYL GROUP; QUINONE DERIVATIVE; UNCLASSIFIED DRUG;

ARTICLE; CHEMICAL STRUCTURE; CHINESE MEDICINE; COMPUTER MODEL; CONTROLLED STUDY; DATA BASE; DRUG BINDING; DRUG METABOLISM; DRUG POTENCY; DRUG SELECTIVITY; DRUG STRUCTURE; ENZYME INHIBITION; ENZYME STRUCTURE; IC 50; MOLECULAR DOCKING; PHARMACOPHORE; RHEUM; STRUCTURE ACTIVITY RELATION;

ANIMALS; CYTOCHROME P-450 ENZYME SYSTEM; ENZYME INHIBITORS; HUMANS; NADP; QUINONES; RATS;

RHEUM AUSTRALE;

EID: 84859786014     PISSN: 0893228X     EISSN: 15205010     Source Type: Journal    
DOI: 10.1021/tx2004163     Document Type: Article

References (44)

1. Guengerich, F. P. (2004) Cytochrome P450: What have we learned and what are the future issues? Drug Metab. Rev. 36, 159-197. (Pubitemid 38802485)
2. Nelson, D. R., Koymans, L., Kamataki, T., Stegeman, J. J., Feyereisen, R., Waxman, D. J., Waterman, M. R., Gotoh, O., Coon, M. J., Estabrook, R. W., Gunsalus, I. C., and Nebert, D. W. (1996) P450 superfamily: Update on new sequences, gene mapping, accession numbers and nomenclature. Pharmacogenetics 6, 1-42. (Pubitemid 26096749)
3. Hashizume, T., Imaoka, S., Mise, M., Terauchi, Y., Fujii, T., Miyazaki, H., Kamataki, T., and Funae, Y. (2002) Involvement of CYP2J2 and CYP4F12 in the metabolism of ebastine in human intestinal microsomes. J. Pharmacol. Exp. Ther. 300, 298-304. (Pubitemid 34028540)
4. Wang, H. W., Chen, T. L., Yang, P. C., and Ueng, T. H. (2001) Induction of cytochromes P450 1A1 and 1B1 by emodin in human lung adenocarcinoma cell line CL5. Drug Metab. Dispos. 29, 1229-1235.
5. Murray, G. I. (2000) The role of cytochrome P450 in tumour development and progression and its potential in therapy. J. Pathol. 192, 419-426.
6. Gibson, P., Gill, J. H., Khan, P. A., Seargent, J. M., Martin, S. W., Batman, P. A., Griffith, J., Bradley, C., Double, J. A., Bibby, M. C., and Loadman, P. M. (2003) Cytochrome P450 1B1 (CYP1B1) is overexpressed in human colon adenocarcinomas relative to normal colon: implications for drug development. Mol. Cancer Ther. 2, 527-534.
7. Tokizane, T., Shiina, H., Igawa, M., Enokida, H., Urakami, S., Kawakami, T., Ogishima, T., Okino, S. T., Li, L. C., Tanaka, Y., Nonomura, N., Okuyama, A., and Dahiya, R. (2005) Cytochrome P450 1B1 is overexpressed and regulated by hypomethylation in prostate cancer. Clin. Cancer Res. 11, 5793-5801. (Pubitemid 41170305)
8. Marks, K. M., Park, E. S., Arefolov, A., Russo, K., Ishihara, K., Ring, J. E., Clardy, J., Clarke, A. S., and Pelish, H. E. (2011) The selectivity of austocystin D arises from cell-line-specific drug activation by cytochrome P450 enzymes. J. Nat. Prod. 74, 567-573.
9. Shatalova, E. G., Klein-Szanto, A. J., Devarajan, K., Cukierman, E., and Clapper, M. L. (2011) Estrogen and cytochrome P450 1B1 contribute to both early- and late-stage head and neck carcinogenesis. Cancer Prev. Res. (Phila) 4, 107-115.
10. Gomez, A., Nekvindova, J., Travica, S., Lee, M. Y., Johansson, I., Edler, D., Mkrtchian, S., and Ingelman-Sundberg, M. (2010) Colorectal cancer-specific cytochrome P450 2W1: Intracellular localization, glycosylation, and catalytic activity. Mol. Pharmacol. 78, 1004-1011.
11. Murray, G. I., Taylor, M. C., McFadyen, M. C., McKay, J. A., Greenlee, W. F., Burke, M. D., and Melvin, W. T. (1997) Tumorspecific expression of cytochrome P450 CYP1B1. Cancer Res. 57, 3026-3031. (Pubitemid 27315056)
12. Karlgren, M., Gomez, A., Stark, K., Svard, J., Rodriguez-Antona, C., Oliw, E., Bernal, M. L., Ramony Cajal, S., Johansson, I., and Ingelman-Sundberg, M. (2006) Tumor-specific expression of the novel cytochrome P450 enzyme, CYP2W1. Biochem. Biophys. Res. Commun. 341, 451-458. (Pubitemid 43152125)
13. Aung, P. P., Oue, N., Mitani, Y., Nakayama, H., Yoshida, K., Noguchi, T., Bosserhoff, A. K., and Yasui, W. (2006) Systematic search for gastric cancer-specific genes based on SAGE data: Melanoma inhibitory activity and matrix metalloproteinase-10 are novel prognostic factors in patients with gastric cancer. Oncogene 25, 2546-2557.
14. Alexander, D. L., Zhang, L., Foroozesh, M., Alworth, W. L., and Jefcoate, C. R. (1999) Metabolism-based polycyclic aromatic acetylene inhibition of CYP1B1 in 10T1/2 cells potentiates aryl hydrocarbon receptor activity. Toxicol. Appl. Pharmacol. 161, 123-139.
15. Zhu, N., Lightsey, D., Foroozesh, M., Alworth, W., Chaudhary, A., Willett, K. L., and Klein Stevens, C. L. (2006) Naphthoflavone propargyl ether inhibitors of cytochrome P450. J. Chem. Crystallogr. 36, 289-296. (Pubitemid 44198340)
16. McKendall, M., Smith, T., Anh, K., Ellis, J., McGee, T., Foroozesh, M., Zhu, N., and Klein Stevens, C. L. (2008) Methoxyflavone inhibitors of cytochrome P450. J. Chem. Crystallogr. 38, 231-237.
17. Roberts, E. S., Hopkins, N. E., Foroozesh, M., Alworth, W. L., Halpert, J. R., and Hollenberg, P. F. (1997) Inactivation of cytochrome P450s 2B1, 2B4, 2B6, and 2B11 by arylalkynes. Drug Metab. Dispos. 25, 1242-1248. (Pubitemid 27490667)
18. Shimada, T., Murajama, N., Tanaka, K., Takenaka, S., Imai, Y., Hopkins, N. E., Foroozesh, M. K., Alworth, W. L., Yamazaki, H., Guengerich, F. P., and Komori, M. (2008) Interaction of polycyclic aromatic hydrocarbons with human cytochrome P450 1B1 in inhibiting catalytic activity. Chem. Res. Toxicol. 21, 2313-2323.
19. Shimada, T., Yamazaki, H., Foroozesh, M., Hopkins, N. E., Alworth, W. L., and Guengerich, F. P. (1998) Selectivity of polycyclic inhibitors for human cytochrome P450s 1A1, 1A2, and 1B1. Chem. Res. Toxicol. 11, 1048-1056. (Pubitemid 28447294)
20. Zhu, N., Lightsey, D., Liu, J., Foroozesh, M., Morgan, K. M., Stevens, E. D., and Klein Stevens, C. L. (2010) Ethynyl and Propynylpyrene Inhibitors of Cytochrome P450. J. Chem. Crystallogr. 40, 343-352.
21. Strobel, S. M., Szklarz, G. D., He, Y., Foroozesh, M., Alworth, W. L., Roberts, E. S., Hollenberg, P. F., and Halpert, J. R. (1999) Identification of selective mechanism-based inactivators of cytochromes P-450 2B4 and 2B5, and determination of the molecular basis for differential susceptibility. J. Pharmacol. Exp. Ther. 290, 445-451. (Pubitemid 29302355)
22. Sridhar, J., Jin, P., Liu, J., Foroozesh, M., and Stevens, C. L. (2010) In silico studies of polyaromatic hydrocarbon inhibitors of cytochrome P450 enzymes 1A1, 1A2, 2A6, and 2B1. Chem. Res. Toxicol. 23, 600-607.
23. Sridhar, J., Foroozesh, M., and Stevens, C. K. (2011) QSAR Models of Cytochrome P450 Enzyme 1A2 Inhibitors using CoMFA, CoMSIA and HQSAR. SAR QSAR Environ. Res. 22, 681-697.
24. Mueller, S. O., Stopper, H., and Dekant, W. (1998) Biotransformation of the anthraquinones emodin and chrysophanol by cytochrome P450 enzymes. Bioactivation to genotoxic metabolites. Drug Metab. Dispos. 26, 540-546. (Pubitemid 28498359)
25. Sun, M., Sakakibara, H., Ashida, H., Danno, G., and Kanazawa, K. (2000) Cytochrome P4501A1-inhibitory action of antimutagenic anthraquinones in medicinal plants and the structure-activity relationship. Biosci., Biotechnol., Biochem. 64, 1373-1378.
26. Srinivas, G., Anto, R. J., Srinivas, P., Vidhyalakshmi, S., Senan, V. P., and Karunagaran, D. (2003) Emodin induces apoptosis of human cervical cancer cells through poly(ADP-ribose) polymerase cleavage and activation of caspase-9. Eur. J. Pharmacol. 473, 117-125. (Pubitemid 36929875)
27. Su, Y. T., Chang, H. L., Shyue, S. K., and Hsu, S. L. (2005) Emodin induces apoptosis in human lung adenocarcinoma cells through a reactive oxygen species-dependent mitochondrial signaling pathway. Biochem. Pharmacol. 70, 229-241.
28. Chen, Y. C., Shen, S. C., Lee, W. R., Hsu, F. L., Lin, H. Y., Ko, C. H., and Tseng, S. W. (2002) Emodin induces apoptosis in human promyeloleukemic HL-60 cells accompanied by activation of caspase 3 cascade but independent of reactive oxygen species production. Biochem. Pharmacol. 64, 1713-1724.
29. Zhang, L., Lau, Y. K., Xi, L., Hong, R. L., Kim, D. S., Chen, C. F., Hortobagyi, G. N., Chang, C., and Hung, M. C. (1998) Tyrosine kinase inhibitors, emodin and its derivative repress HER-2/neu-induced cellular transformation and metastasis-associated properties. Oncogene 16, 2855-2863. (Pubitemid 28383270)
30. Lee, H. Z. (2001) Effects and mechanisms of emodin on cell death in human lung squamous cell carcinoma. Br. J. Pharmacol. 134, 11-20.
31. Yi, J., Yang, J., He, R., Gao, F., Sang, H., Tang, X., and Ye, R. D. (2004) Emodin enhances arsenic trioxide-induced apoptosis via generation of reactive oxygen species and inhibition of survival signaling. Cancer Res. 64, 108-116. (Pubitemid 38114088)
32. Burke, M. D., Thompson, S., Weaver, R. J., Wolf, C. R., and Mayer, R. T. (1994) Cytochrome P450 specificities of alkoxyresorufin O-dealkylation in human and rat liver. Biochem. Pharmacol. 48, 923-936. (Pubitemid 24285170)
33. Tu, Y., Deshmukh, R., Sivaneri, M., and Szklarz, G. D. (2008) Application of molecular modeling for prediction of substrate specificity in cytochrome P450 1A2 mutants. Drug Metab. Dispos. 36, 2371-2380.
34. Buters, J. T., Schiller, C. D., and Chou, R. C. (1993) A highly sensitive tool for the assay of cytochrome P450 enzyme activity in rat, dog and man. Direct fluorescence monitoring of the deethylation of 7-ethoxy-4- trifluoromethylcoumarin. Biochem. Pharmacol. 46, 1577-1584. (Pubitemid 23338491)
35. DeLuca, J. G., Dysart, G. R., Rasnick, D., and Bradley, M. O. (1988) A direct, highly sensitive assay for cytochrome P-450 catalyzed O-deethylation using a novel coumarin analog. Biochem. Pharmacol. 37, 1731-1739.
36. Hopkins, N. E., Foroozesh, M. K., and Alworth, W. L. (1992) Suicide inhibitors of cytochrome P450 1A1 and P450 2B1. Biochem. Pharmacol. 44, 787-796.
37. Foroozesh, M., Primrose, G., Guo, Z., Bell, L. C., Alworth, W. L., and Guengerich, F. P. (1997) Aryl acetylenes as mechanism-based inhibitors of cytochrome P450-dependent monooxygenase enzymes. Chem. Res. Toxicol. 10, 91-102. (Pubitemid 27044913)
38. Oda, A., Yamaotsu, N., and Hirono, S. (2005) New AMBER force field parameters of heme iron for cytochrome P450s determined by quantum chemical calculations of simplified models. J. Comput. Chem. 26, 818-826. (Pubitemid 40751576)
39. Gill, P., and Wright, M. (1981) Practical Optimization, Academic Press, London.
40. Denton, T. T., Zhang, X., and Cashman, J. R. (2005) 5-Substituted, 6-substituted, and unsubstituted 3-heteroaromatic pyridine analogues of nicotine as selective inhibitors of cytochrome P-450 2A6. J. Med. Chem. 48, 224-239. (Pubitemid 40105261)
41. Kim, D., and Guengerich, F. P. (2005) Cytochrome P450 activation of arylamines and heterocyclic amines. Annu. Rev. Pharmacol. Toxicol. 45, 27-49. (Pubitemid 40261797)
42. Peng, J. Z., Remmel, R. P., and Sawchuk, R. J. (2004) Inhibition of murine cytochrome P4501A by tacrine: in vitro studies. Drug Metab. Dispos. 32, 805-812. (Pubitemid 38955609)
43. Ling, K. H., and Hanzlik, R. P. (1989) Deuterium isotope effects on toluene metabolism. Product release as a rate-limiting step in cytochrome P-450 catalysis. Biochem. Biophys. Res. Commun. 160, 844-849.
44. Kunze, K. L., and Trager, W. F. (1993) Isoform-selective mechanism-based inhibition of human cytochrome P450 1A2 by furafylline. Chem. Res. Toxicol. 6, 649-656. (Pubitemid 23290017)